OBJECTIVE： To observe the clinical efficacy and safety of caspofungin acetate in the treatment of invasive pulmonary fungal infection （IPFI）. METHODS： 70 patients with IPFI were selected and randomly divided into observation group （40 cases） and control group （30 cases）. Control group was given Itraconazole injection with initial dose of 250 mg， bid， decreasing to 200 mg， qd， 2 days later； observation group was given Caspofungin acetate injection 70 mg on the first day， decreasing to 50 mg， ivgtt， qd， within 1 h. Clinical efficacy， the rate of nacterial smear negative conversion and ADR were observed in 2 groups. RESULTS： The total effective rate of observation group was 92.50％， which was significantly higher than that of control group （76.67％）； the rate of nacterial smear negative conversion was 72.00％ in observation group， which was significantly higher than that of control group （42.10％）； the incidence of ADR was 7.50％ in observation group， which was significantly lower than that of control group （13.33％）， with statistical significance （P＜0.05）. CONCLUSIONS： Caspofungin acetate is effective for IPFI with low incidence of ADR.